Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

Bank of America started coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report released on Tuesday. The brokerage issued an underperform rating and a $5.00 target price on the ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr.

Sage Therapeutics shares last traded at $7.27, with a volume of 1,302,493 shares trading hands. Wall Street Analysts Forecast Growth Several analysts have recently commented on SAGE shares.

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Philadelphia, Pennsylvania-- (Newsfile Corp. - March 8, 2025) - Grabar Law Office is investigating claims on behalf of Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholders. The investigation concerns ...

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at where Sage Therapeutics, Inc.

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21 ...

Cambridge, MA-based Sage Therapeutics, Inc. has announced the resignation of its Chief Medical (TASE:BLWV) Officer (CMO), Laura Gault, M.D., Ph.D., effective March 21 ...